{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:09:45Z","timestamp":1792706985174,"version":"4.5.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Placenta"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.placenta.2026.05.024","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T07:31:38Z","timestamp":1779780698000},"page":"116-122","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Transplacental transfer of osimertinib and alectinib using an ex vivo human placental perfusion model"],"prefix":"10.1016","volume":"182","author":[{"given":"Laure","family":"Benoit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Combarel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-No\u00eblle","family":"Dieudonne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoann","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estelle","family":"Heggarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Mir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislas","family":"Grassin Delyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Lamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Paci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Vialard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Berveiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.placenta.2026.05.024_bib1","doi-asserted-by":"crossref","DOI":"10.1007\/s11912-020-0862-7","article-title":"Pregnancy and cancer: the INCIP project","volume":"22","author":"Maggen","year":"2020","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.placenta.2026.05.024_bib2","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.lungcan.2011.08.008","article-title":"Successful pregnancy with epidermal growth factor receptor tyrosine kinase inhibitor treatment of metastatic lung adenocarcinoma presenting with respiratory failure","volume":"74","author":"Lee","year":"2011","journal-title":"Lung Cancer"},{"key":"10.1016\/j.placenta.2026.05.024_bib3","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1097\/AOG.0b013e3182a057a2","article-title":"Incidence of pregnancy-associated cancer in Denmark, 1977-2006","volume":"122","author":"Eibye","year":"2013","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.placenta.2026.05.024_bib4","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/IGC.0000000000000904","article-title":"Frequency of pregnancy related cancer: a population based linkage study in lombardy, Italy","volume":"27","author":"Parazzini","year":"2017","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.placenta.2026.05.024_bib5","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.3390\/ijerph18063100","article-title":"Incidence of pregnancy-associated cancer in two Canadian provinces: a population-based study","volume":"18","author":"Metcalfe","year":"2021","journal-title":"Int. J. Environ. Res. Publ. Health"},{"key":"10.1016\/j.placenta.2026.05.024_bib6","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdt199","article-title":"Cancer, pregnancy and fertility: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Peccatori","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.placenta.2026.05.024_bib7","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.1080\/14767058.2018.1461830","article-title":"Lung adenocarcinoma during pregnancy: clinical case and literature review","volume":"32","author":"Bellido","year":"2019","journal-title":"J. Matern. Neonatal Med."},{"key":"10.1016\/j.placenta.2026.05.024_bib8","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1200\/JCO.2017.74.7576","article-title":"Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer","volume":"36","author":"Ramalingam","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.placenta.2026.05.024_bib9","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.annonc.2021.08.1994","article-title":"Early and locally advanced non-small-cell lung cancer: an update of the ESMO clinical practice guidelines focusing on diagnosis, staging, systemic and local therapy","volume":"32","author":"Remon","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.placenta.2026.05.024_bib10","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.placenta.2026.05.024_bib11","article-title":"Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-Rearranged non-small cell lung cancer","volume":"2022","author":"Cameron","year":"2022","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.placenta.2026.05.024_bib12","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.lungcan.2014.06.003","article-title":"Efficacy and safety of gefitinib during pregnancy: case report and literature review","volume":"85","author":"Gil","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.placenta.2026.05.024_bib13","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.pulmoe.2018.03.007","article-title":"Lung cancer in pregnancy \u2013 report of a case treated with crizotinib","volume":"24","author":"Padr\u00e3o","year":"2018","journal-title":"Pulmonology"},{"key":"10.1016\/j.placenta.2026.05.024_bib14","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1001\/jamaoncol.2015.1300","article-title":"Successful treatment of non-small cell lung cancer with erlotinib throughout pregnancy","volume":"1","author":"Ji","year":"2015","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.placenta.2026.05.024_bib15","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.lungcan.2007.10.025","article-title":"Erlotinib administration for advanced non-small cell lung cancer during the first 2 months of unrecognized pregnancy","volume":"60","author":"Zambelli","year":"2008","journal-title":"Lung Cancer"},{"key":"10.1016\/j.placenta.2026.05.024_bib16","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.lungcan.2012.03.026","article-title":"Use of erlotinib throughout pregnancy: a case-report of a patient with metastatic lung adenocarcinoma","volume":"77","author":"Rivas","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.placenta.2026.05.024_bib17","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.lungcan.2021.09.001","article-title":"Use of tyrosine kinase inhibitors during pregnancy for oncogenic-driven advanced non-small cell lung carcinoma","volume":"161","author":"Boudy","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.placenta.2026.05.024_bib18","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1080\/0284186X.2018.1497302","article-title":"Antineoplastic treatment with crizotinib during pregnancy: a case report","volume":"58","author":"Jensen","year":"2019","journal-title":"Acta Oncol. (Madr.)"},{"key":"10.1016\/j.placenta.2026.05.024_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2023.1108124","article-title":"Case report: osimertinib administration during pregnancy in a woman with advanced EGFR-mutant non-small cell lung cancer","volume":"13","author":"Soberanis Pina","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.placenta.2026.05.024_bib20","first-page":"1","article-title":"A pregnant patient with ALK-positive non-small cell lung cancer treated with alectinib: a case report and review of the literature","volume":"25","author":"de Smedt","year":"2023","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.placenta.2026.05.024_bib21","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.jtho.2021.02.005","article-title":"First case report of pregnancy on alectinib in a woman with metastatic ALK-rearranged lung cancer: a case report","volume":"16","author":"Scarfone","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.placenta.2026.05.024_bib22","article-title":"Two uncomplicated pregnancies on alectinib in a woman with metastatic ALK-rearranged NSCLC: a case report","volume":"3","author":"Weidenbaum","year":"2022","journal-title":"JTO Clin. Res. Rep."},{"key":"10.1016\/j.placenta.2026.05.024_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13061238","article-title":"Cancer during pregnancy: a review of preclinical and clinical transplacental transfer of anticancer agents","volume":"13","author":"Benoit","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.placenta.2026.05.024_bib24","article-title":"Guidance for industry - pharmacokinetics in pregnancy - study design, data analysis, and impact on dosing and labeling","year":"2004","journal-title":"Food and Drug Administration Guidance for Industry- 2004-D-0459, 3-5"},{"key":"10.1016\/j.placenta.2026.05.024_bib25","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1080\/17425255.2017.1401064","article-title":"Pharmacokinetic drug evaluation of osimertinib for the treatment of non-small cell lung cancer","volume":"13","author":"Rossi","year":"2017","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.placenta.2026.05.024_bib26","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s40262-018-0689-7","article-title":"Clinical pharmacokinetics of Anaplastic lymphoma kinase inhibitors in non-small-cell lung cancer","volume":"58","author":"Hirota","year":"2019","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.placenta.2026.05.024_bib27","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1159\/000410667","article-title":"Criteria for evaluating perfusion experiments and presentation of results","volume":"13","author":"Challier","year":"1985","journal-title":"Contrib. Gynecol. Obstet."},{"key":"10.1016\/j.placenta.2026.05.024_bib28","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/0002-9378(72)90909-X","article-title":"Transfer across the perfused human placenta of antipyrine, sodium, and leucine","volume":"114","author":"Schneider","year":"1972","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"92","key":"10.1016\/j.placenta.2026.05.024_bib29","article-title":"Transplacental transfer of oseltamivir and its metabolite using the human perfused placental cotyledon model","volume":"206","author":"Berveiller","year":"2012","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.placenta.2026.05.024_bib30","doi-asserted-by":"crossref","first-page":"514.e1","DOI":"10.1016\/j.ajog.2012.10.007","article-title":"Comparative transplacental transfer of taxanes using the human perfused cotyledon placental model","volume":"207","author":"Berveiller","year":"2012","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.placenta.2026.05.024_bib31","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1002\/cncr.23935","article-title":"Use of platinum derivatives during pregnancy","volume":"113","author":"Mir","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.placenta.2026.05.024_bib32","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/cpdd.296","article-title":"Effect of food and esomeprazole on the pharmacokinetics of alectinib, a highly selective ALK inhibitor, in healthy subjects","volume":"6","author":"Morcos","year":"2017","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.placenta.2026.05.024_bib33","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2165\/00003088-200443080-00001","article-title":"Drug transfer and metabolism by the human placenta","volume":"43","author":"Syme","year":"2004","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.placenta.2026.05.024_bib34","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.placenta.2004.05.013","article-title":"P-glycoprotein expression of the human placenta during pregnancy","volume":"26","author":"Gil","year":"2005","journal-title":"Placenta"},{"key":"10.1016\/j.placenta.2026.05.024_bib35","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1158\/1535-7163.MCT-15-0939","article-title":"Osimertinib (AZD9291) enhanced the efficacy of chemotherapeutic agents in ABCB1- and ABCG2-Overexpressing cells in vitro, in vivo, and Ex vivo","volume":"15","author":"Chen","year":"2016","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.placenta.2026.05.024_bib36","doi-asserted-by":"crossref","DOI":"10.1038\/emm.2016.168","article-title":"Alectinib (CH5424802) antagonizes ABCB1- and ABCG2-mediated multidrug resistance in vitro, in vivo and ex vivo","volume":"49","author":"Yang","year":"2017","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.placenta.2026.05.024_bib37","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s10637-018-0677-7","article-title":"Chemotherapy in pregnancy: exploratory study of the effects of paclitaxel on the expression of placental drug transporters","volume":"37","author":"Berveiller","year":"2019","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.placenta.2026.05.024_bib38","series-title":"Annexe I R\u00e9sum\u00e9 Des Caract\u00e9ristiques Du Produit Kalydeco","first-page":"1","year":"2008"},{"key":"10.1016\/j.placenta.2026.05.024_bib39","first-page":"1","article-title":"Osimertinib (Tagrisso)","volume":"2","year":"2022","journal-title":"Can. J. Heal Technol."},{"key":"10.1016\/j.placenta.2026.05.024_bib40","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.reprotox.2010.01.006","article-title":"Quality assessment of a placental perfusion protocol","volume":"30","author":"Mathiesen","year":"2010","journal-title":"Reprod. Toxicol."},{"key":"10.1016\/j.placenta.2026.05.024_bib41","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.reprotox.2010.04.006","article-title":"Preliminary interlaboratory comparison of the ex vivo dual human placental perfusion system","volume":"30","author":"Myllynen","year":"2010","journal-title":"Reprod. Toxicol."},{"key":"10.1016\/j.placenta.2026.05.024_bib42","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.tiv.2012.08.027","article-title":"Placental transfer and metabolism: an overview of the experimental models utilizing human placental tissue","volume":"27","author":"Myllynen","year":"2013","journal-title":"Toxicol. Vitro"},{"key":"10.1016\/j.placenta.2026.05.024_bib43","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s10549-012-2368-y","article-title":"Trastuzumab administration during pregnancy: a systematic review and meta-analysis","volume":"137","author":"Zagouri","year":"2013","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.placenta.2026.05.024_bib44","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1056\/NEJMc072213","article-title":"Trastuzumab--mechanism of action and use","volume":"357","author":"Mir","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.placenta.2026.05.024_bib45","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s10549-012-1996-6","article-title":"Pregnancy occurring during or following adjuvant trastuzumab in patients enrolled in the HERA trial (BIG 01-01)","volume":"133","author":"Azim","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.placenta.2026.05.024_bib46","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1093\/toxsci\/kfx063","article-title":"Placental disposition and effects of crizotinib: an ex vivo study in the isolated dual-side perfused human cotyledon","volume":"157","author":"Eliesen","year":"2017","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.placenta.2026.05.024_bib47","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1093\/annonc\/mdv172","article-title":"Variation in transplacental transfer of tyrosine kinase inhibitors in the human perfused cotyledon model","volume":"26","author":"Jovelet","year":"2015","journal-title":"Ann. Oncol."}],"container-title":["Placenta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0143400426001864?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0143400426001864?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T08:44:53Z","timestamp":1786092293000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0143400426001864"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":47,"alternative-id":["S0143400426001864"],"URL":"https:\/\/doi.org\/10.1016\/j.placenta.2026.05.024","relation":{},"ISSN":["0143-4004"],"issn-type":[{"value":"0143-4004","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transplacental transfer of osimertinib and alectinib using an ex vivo human placental perfusion model","name":"articletitle","label":"Article Title"},{"value":"Placenta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.placenta.2026.05.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}